These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9934481)

  • 1. Tricyclic ureas: a new class of HIV-1 protease inhibitors.
    Han W; Pelletier JC; Hodge CN
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3615-20. PubMed ID: 9934481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
    Patel M; Rodgers JD; McHugh RJ; Johnson BL; Cordova BC; Klabe RM; Bacheler LT; Erickson-Viitanen S; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3217-20. PubMed ID: 10576691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
    Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
    J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
    Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
    Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status of HIV protease inhibitors].
    Yang QG; He XC; Bai DL
    Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778
    [No Abstract]   [Full Text] [Related]  

  • 6. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
    Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
    Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-peptidic HIV protease inhibitors.
    Chrusciel RA; Strohbach JW
    Curr Top Med Chem; 2004; 4(10):1097-114. PubMed ID: 15193141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK
    J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
    Rodgers JD; Lam PY; Johnson BL; Wang H; Li R; Ru Y; Ko SS; Seitz SP; Trainor GL; Anderson PS; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Wright MR; Chang CH; Erickson-Viitanen S
    Chem Biol; 1998 Oct; 5(10):597-608. PubMed ID: 9818151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
    Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
    Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
    J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmentally benign synthesis of unsymmetrical ureas and their evaluation as potential HIV-1 protease inhibitors via a computational approach.
    Lotha TN; Richa K; Sorhie V; Ketiyala ; Nakro V; Imkongyanger ; Ritse V; Rudithongru L; Namsa ND; Jamir L
    Mol Divers; 2024 Apr; 28(2):749-763. PubMed ID: 36788191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study.
    Hilgeroth A; Fleischer R; Wiese M; Heinemann FW
    J Comput Aided Mol Des; 1999 May; 13(3):233-42. PubMed ID: 10216831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
    J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular recognition of cyclic urea HIV-1 protease inhibitors.
    Ala PJ; DeLoskey RJ; Huston EE; Jadhav PK; Lam PY; Eyermann CJ; Hodge CN; Schadt MC; Lewandowski FA; Weber PC; McCabe DD; Duke JL; Chang CH
    J Biol Chem; 1998 May; 273(20):12325-31. PubMed ID: 9575185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-membered cyclic ureas as HIV-1 protease inhibitors: a QSAR study based on CODESSA PRO approach. Quantitative structure-activity relationships.
    Katritzky AR; Oliferenko A; Lomaka A; Karelson M
    Bioorg Med Chem Lett; 2002 Dec; 12(23):3453-7. PubMed ID: 12419382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors.
    Gupta SP; Babu MS; Garg R; Sowmya S
    J Enzyme Inhib; 1998 Sep; 13(6):399-407. PubMed ID: 9825304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.